Abstract:In pediatric age and particularly in newborn infants the drug efficacy and safety are influenced by the growth and development on drug Absorption, Distribution, Metabolism and Excretion (ADME). Thanks to the fast development of pharmacogenomics and pharmacogenetics, the drug therapy promises to be adapted to the genetic profile of the individual, reducing considerably the side effects of drugs and increasing their efficacy. Interindividual variability in drug response is well known in both adults and children. Such a variability is multifactorial considering both intrinsic and extrinsic factors. Drug distribution in the neonate is influenced by a variety of age-dependent factors as a total body water content and distribution variations, role of drug transporters, blood/tissue protein binding, blood and tissue pH and perfusion. The development of enzymes involved in human metabolism were classified in 3 categories: 1) those expressed during the whole or part of the fetal period, but silenced or expressed at low levels within 1-2 years after birth; 2) those expressed at relatively constant levels throughout fetal development, but increased to some extent postnatally; and 3) those whose onset of expression can occur in the third trimester, but substantial increase is noted in the first 1-2 years after birth. Besides this intrinsic aspects influencing pharmacokinetics during the neonatal period there are other important events such as inborn or acquired diseases, environment and finally pharmacogenetics and pharmacogenomics. Thousands of deaths every years are caused by fatal drug reactions; among the potential causes there are not only the severity of the disease being treated, drug interactions, nutritional status, renal and liver functions, but also the inherited differences in drug metabolism and genetic polymorphism. Adverse drug reactions (ADRs) among pediatric patients have been shown to be three times more frequent than in adults. On August 2010 The National Institute of Child Health and Human Development (NICHD) addressed patient safety issues in the NICU, recognizing that to understand and prevent adverse events, systematic research and education in safety issues needed. From all these concepts in terms of ADME, pharmacogenetics (relative to a single gene) and pharmacogenomics (relative to many genes) it is becoming more evident the perspective of the new concept of individualized medicine. The goal of this should be to identify which group of patients responds positively, which patients are nonresponders and who experiences adverse reaction for the same drug and dose. The interindividual variability in response to any drug is mostly dependent on DNA sequence variations across the human genome, the haplotype map (HAPMAP). At present there is still a big distance beween the knowledge in genetic and the practical application to model the drug profile to the genetic/genomic profile of the single patient. In the neonatal period the effects of growth in the pharmacodynamic, processes can help optimizing the dosage of neonatal frequently used medicines, thereby, minimizing their toxicity and increasing their efficacy. It should be useful to create accurate dosage adjustments according to the week of development.

[Optimization of Drug Administration in Special Populations Focusing on Drug Distribution].

[Antimicrobial Dosing Individualization Based on Pharmacokinetic/Pharmacodynamic Evaluation, Considering Factors of "Patient", "Site of infection" and "Microorganism"]

Central Nervous System Medications: Pharmacokinetic and Pharmacodynamic Considerations for Older Adults

Developmental Pharmacokinetics in Pediatric Populations.

Application of pharmacokinetics to guide the clinical trial of drugs in special population

Pharmacokinetics and drug metabolism in the elderly

An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients

Pharmacokinetic-Pharmacodynamic Crisis in the Elderly

The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro

Population Pharmacokinetic Analysis and Dosing Optimization Based on Unbound Daptomycin Concentration and Cystatin C in Nonobese Elderly Patients with Hypoalbuminemia and Chronic Kidney Disease

When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly

Ontogeny and drug metabolism in newborns

Analysis on Drugs Application in Elderly Patients with Renal Insufficiency

New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development

Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection

Trends of in vitro pharmacological potency and in vivo pharmacokinetics parameters of modern drugs: Can the therapeutic/subtherapeutic dose be estimated from in vitro Ki and pharmacokinetic parameters?

Physiologically Based Pharmacokinetic Model for Older Adults and Its Application in Geriatric Drug Research

Model‐informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations

Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria

Current status and usefulness of therapeutic drug monitoring implementation of theophylline in elderly patients based on a nationwide database study and modeling approach

Dose Optimization of Piperacillin/tazobactam in Patients with Renal Dysfunction Based on Population Pharmacokinetic and Pharmacodynamic Simulations